CRUSH ReportsCRUSH Alerts 2.0CRUSH Industry ReportsCRUSHarmyContact Manager ApplicationMid-Market Manager ApplicationTarget Builder Application
 

Abbott Laboratories (ABT)

The Abbott Laboratories CRUSH Report is a Fortune 1000 deep dive sales intelligence company profile and will help increase your sales leads and add more accounts in your sales pipeline while eliminating costly research time.

The Abbott Laboratories CRUSH Report contains insights to IT architectures, business and technology initiatives, corporate strategies, projects and budgets, org charts and key decision-maker contact info.

The Abbott Laboratories CRUSH Report allows IT sales and marketing professionals to:
  • Jump-start sales cycles in net new accounts
  • Expand footprints in existing customer accounts
  • Facilitate the strategic account planning process
  • Respond to RFPs & bids more effectively
  • Build better content into executive level presentations
  • Identify the presence of competitors & partners
The Abbott Laboratories CRUSH Report has the competitive intelligence needed for account planning within the Fortune 1000. Target the right people, with the right message at the right time using our org charts, decision maker contact info, business drivers and IT landscapes.

Click here to download free sample CRUSH Reports

Abbott.com

Press Releases

Abbott Launches PediaSure SideKicks® Clear for Picky Eaters
Wednesday May 16th 2012 07:00:00 AM

Abbott Launches PediaSure SideKicks® Clear for Picky Eaters

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Tuesday May 15th 2012 07:00:00 AM

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Reaches Settlement Agreement on Depakote
Monday May 7th 2012 07:00:00 AM

Abbott Reaches Settlement Agreement on Depakote

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Recognizes Winners of Supplier Excellence Award
Friday May 4th 2012 07:00:00 AM

Abbott Recognizes Winners of Supplier Excellence Award

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
Thursday May 3rd 2012 01:00:00 PM

Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury
Thursday May 3rd 2012 07:00:00 AM

Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott to Present at Deutsche Bank 37th Annual Health Care Conference
Wednesday May 2nd 2012 07:00:00 AM

Abbott to Present at Deutsche Bank 37th Annual Health Care Conference

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

New Products from Abbott’s EAS® Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals
Wednesday April 25th 2012 07:00:00 AM

New Products from Abbott’s EAS® Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States
Monday April 23rd 2012 07:00:00 AM

Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery
Friday April 20th 2012 01:00:00 PM

Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C
Thursday April 19th 2012 01:00:00 PM

Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C
Thursday April 19th 2012 07:00:00 AM

Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter; Raises Full-Year 2012 Outlook
Wednesday April 18th 2012 07:00:00 AM

Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter; Raises Full-Year 2012 Outlook

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer
Tuesday April 17th 2012 07:00:00 AM

Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott’s Investigational Treatment for Advanced Parkinson’s Disease Demonstrates Positive Results in Phase 3 Clinical Trial
Tuesday April 17th 2012 07:00:00 AM

Abbott’s Investigational Treatment for Advanced Parkinson’s Disease Demonstrates Positive Results in Phase 3 Clinical Trial

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)
Wednesday April 11th 2012 07:00:00 AM

Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan
Monday April 9th 2012 07:00:00 AM

Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C
Wednesday April 4th 2012 07:00:00 AM

Abbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott's PLEX-ID Molecular System and Tests for Broad Microbial Identification Obtain CE Marking
Friday March 30th 2012 07:00:00 AM

Abbott's PLEX-ID Molecular System and Tests for Broad Microbial Identification Obtain CE Marking

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Hosts Conference Call for First-Quarter Earnings
Wednesday March 28th 2012 07:00:00 AM

Abbott Hosts Conference Call for First-Quarter Earnings

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company
Wednesday March 21st 2012 01:00:00 PM

Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012
Tuesday March 20th 2012 07:00:00 AM

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis Suppurativa - (U.S.)
Thursday March 15th 2012 07:00:00 AM

Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis Suppurativa - (U.S.)

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis Suppurativa - (Europe)
Thursday March 15th 2012 07:00:00 AM

Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis Suppurativa - (Europe)

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

New Publication Presents Comparative Efficacy Data for Abbott's Zemplar®(paricalcitol) in Treating Secondary Hyperparathyroidism in Hemodialysis Patients
Monday March 12th 2012 07:00:00 AM

New Publication Presents Comparative Efficacy Data for Abbott's Zemplar®(paricalcitol) in Treating Secondary Hyperparathyroidism in Hemodialysis Patients

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System Receives FDA Clearance
Thursday March 8th 2012 07:00:00 AM

Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System Receives FDA Clearance

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott to Present at Barclays Capital 2012 Global Healthcare Conference
Wednesday March 7th 2012 07:00:00 AM

Abbott to Present at Barclays Capital 2012 Global Healthcare Conference

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease
Wednesday March 7th 2012 07:00:00 AM

Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy
Tuesday March 6th 2012 01:00:00 PM

Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Abbott to Collaborate on Rapid Molecular Test to Identify Serious Infections in Bones and Joint
Monday March 5th 2012 07:00:00 AM

Abbott to Collaborate on Rapid Molecular Test to Identify Serious Infections in Bones and Joint

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Decision Chain
Org Charts


Org Chart

Insights to Initiatives, Projects, & Budgets

Decision Maker Contact Info

Contact Info